Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 6
2005 2
2006 1
2008 2
2009 9
2010 14
2011 11
2012 6
2013 3
2014 2
2015 2
2016 5
2017 4
2018 7
2019 2
2020 10
2021 11
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.
Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, Tamura M, Shikata S, Zhang W, Yamamoto K, Kawabata KC, Kawase T, Saito T, Yoshida T, Yamazaki S, Kaito Y, Imai Y, Denda T, Ota Y, Fukuyama T, Tanaka Y, Enomoto Y, Kitamura T, Goyama S. Sugimoto E, et al. Among authors: imai y. Commun Biol. 2023 Dec 21;6(1):1294. doi: 10.1038/s42003-023-05606-3. Commun Biol. 2023. PMID: 38129572 Free PMC article.
Current and Future PET Imaging for Multiple Myeloma.
Ishibashi M, Takahashi M, Yamaya T, Imai Y. Ishibashi M, et al. Among authors: imai y. Life (Basel). 2023 Aug 7;13(8):1701. doi: 10.3390/life13081701. Life (Basel). 2023. PMID: 37629558 Free PMC article. Review.
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma.
Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M, Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H, Inokuchi K, Tamura H. Kinoshita R, et al. Among authors: imai y. Exp Hematol. 2023 May;121:38-47.e2. doi: 10.1016/j.exphem.2023.01.006. Epub 2023 Feb 14. Exp Hematol. 2023. PMID: 36796620
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.
Mikami M, Masuda T, Kanatani T, Noura M, Umeda K, Hiramatsu H, Kubota H, Daifu T, Iwai A, Hattori EY, Furuichi K, Takasaki S, Tanaka S, Matsui Y, Matsuo H, Hirata M, Kataoka TR, Nakahata T, Kuwahara Y, Iehara T, Hosoi H, Imai Y, Takita J, Sugiyama H, Adachi S, Kamikubo Y. Mikami M, et al. Among authors: imai y. Mol Cells. 2022 Dec 31;45(12):886-895. doi: 10.14348/molcells.2022.2031. Epub 2022 Dec 12. Mol Cells. 2022. PMID: 36572559 Free PMC article.
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Masuda T, Maeda S, Shimada S, Sakuramoto N, Morita K, Koyama A, Suzuki K, Mitsuda Y, Matsuo H, Kubota H, Kato I, Tanaka K, Takita J, Hirata M, Kataoka TR, Nakahata T, Adachi S, Hirai H, Mizuta S, Naka K, Imai Y, Kimura S, Sugiyama H, Kamikubo Y. Masuda T, et al. Among authors: imai y. Cancer Sci. 2022 Feb;113(2):529-539. doi: 10.1111/cas.15239. Epub 2021 Dec 28. Cancer Sci. 2022. PMID: 34902205 Free PMC article.
98 results